Antibody drug cost-effective for allergic asthma
NEW YORK (Reuters Health) - The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in the journal Allergy.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=8KyI9I" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=8KyI9I)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=DEkDtI" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=DEkDtI) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=z9LgAi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=z9LgAi) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=iSAoBi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=iSAoBi)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/304130617" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/304130617/idUSTON40247820080604